Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Endocr Relat Cancer. 2019 Nov;26(11):R627–R652. doi: 10.1530/ERC-19-0165

Figure 4. 177Lu-DOTATATE in a SDHB-patient with metastatic jugular paraganglioma.

Figure 4.

A-B: Post-therapy SPECT/CT following 1st administration of 177Lu-DOTATATE. A: SPECT/CT fusion images centered over the jugular PGL (long arrow), B: Volume rendering (jugular PGL: long arrow, metastases: short arrows). C: Pre-therapeutic MRI. D: Post-therapeutic MRI (2-months following the 4th cycle of 177Lu-DOTATATE) showing a tumor shrinkage (asterisk).